Preclinical trial of the antitumoral therapeutic effectiveness of some natural polyphenolic biopreparations. 2000

P Rotinberg, and S Kelemen, and M Gramescu, and H Rotinberg, and V Nuta
Institute of Biological Research, Jassy, Romania.

We have assessed the antitumoral action of the POLYAS I and POLYAS II vegetal polyphenolic biopreparations--separated and purified from Asclepias syriaca leaves - in rats with various experimental tumoral lines. We studied the therapeutic effect of different doses on the tumor generation process and compared it with the experimental oncostatic action of several standard chemotherapeutic drugs of clinical use (thiotepa, methotrexate, melphalan and cyclophosphamide). In our experimental treatment with the bioactive polyphenolic agents, we have used various doses, both higher and lower than the dose that had conditioned the expression of their antitumoral action upon Guerin T-8 lymphotropic epithelioma and upon Walker 256 carcinosarcoma. We found the antineoplastic effectiveness of those aromatic biopreparations from phytomass to be dose-dependent. We compared the evaluation indices of the antitumoral pharmacodynamic effect we obtained in the treatment with the POLYAS biopreparations with those of reference cytostatic agents. The antitumoral potential of the new natural biopreparations is higher than, equal or close to that of the standard oncochemotherapeutic agents. Antitumoral effectiveness can be improved by an experimental manipulation of the therapeutic doses--which proves the existence of a dose-response relationship. POLYAS I and POLYAS II polyphenolic biopreparations are compatible in point of effectiveness with the standard cytostatic agents, a fact that we considered relevant for the characterization of the POLYAS I and POLYAS II vegetal extracts as potential antineoplastic agents. The quantitative preclinical evaluation of the specific pharmacodynamic effect will be complemented by the investigation of the new polyphenolic biopreparations therapeutic effectiveness in tumors with various degrees of development.

UI MeSH Term Description Entries
D008517 Phytotherapy Use of plants or herbs to treat diseases or to alleviate pain. Herb Therapy,Herbal Therapy
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D010636 Phenols Benzene derivatives that include one or more hydroxyl groups attached to the ring structure.
D011108 Polymers Compounds formed by the joining of smaller, usually repeating, units linked by covalent bonds. These compounds often form large macromolecules (e.g., BIOPOLYMERS; PLASTICS). Polymer
D002279 Carcinoma 256, Walker A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed) Carcinosarcoma 256, Walker,Walker Carcinoma 256,Walker Carcinosarcoma 256
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005419 Flavonoids A group of phenyl benzopyrans named for having structures like FLAVONES. 2-Phenyl-Benzopyran,2-Phenyl-Chromene,Bioflavonoid,Bioflavonoids,Flavonoid,2-Phenyl-Benzopyrans,2-Phenyl-Chromenes,2 Phenyl Benzopyran,2 Phenyl Benzopyrans,2 Phenyl Chromene,2 Phenyl Chromenes
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics

Related Publications

P Rotinberg, and S Kelemen, and M Gramescu, and H Rotinberg, and V Nuta
December 1973, Sovetskaia meditsina,
P Rotinberg, and S Kelemen, and M Gramescu, and H Rotinberg, and V Nuta
February 2020, Molecules (Basel, Switzerland),
P Rotinberg, and S Kelemen, and M Gramescu, and H Rotinberg, and V Nuta
April 1974, Veterinarni medicina,
P Rotinberg, and S Kelemen, and M Gramescu, and H Rotinberg, and V Nuta
December 2002, Journal of agricultural and food chemistry,
P Rotinberg, and S Kelemen, and M Gramescu, and H Rotinberg, and V Nuta
May 2002, Journal of investigative medicine : the official publication of the American Federation for Clinical Research,
P Rotinberg, and S Kelemen, and M Gramescu, and H Rotinberg, and V Nuta
June 1961, Biulleten' eksperimental'noi biologii i meditsiny,
P Rotinberg, and S Kelemen, and M Gramescu, and H Rotinberg, and V Nuta
June 1955, Arzneimittel-Forschung,
P Rotinberg, and S Kelemen, and M Gramescu, and H Rotinberg, and V Nuta
April 1970, European journal of cancer,
P Rotinberg, and S Kelemen, and M Gramescu, and H Rotinberg, and V Nuta
January 1971, The Soviet journal of developmental biology,
P Rotinberg, and S Kelemen, and M Gramescu, and H Rotinberg, and V Nuta
November 2011, Pharmaceutics,
Copied contents to your clipboard!